Long-Acting Cabotegravir / Rilpivirine for Individuals With Detectable Viral Loads
Dr. Monica Gandhi shares experience and data from UCSF with prescribing injectable, long-acting cabotegravir/rilpivirine (Cabenuva) for persons with HIV with detectable viral loads and discusses potential benefits and risks of this off-label strategy.
▶︎
Impact of ART Initiation in Acute and Early HIV Results from the Sabes Study in Peru
▶︎
Mini Lecture Series: Long-Acting, Injectable Cabotegravir-Rilpivirine (CAB-RPV)
▶︎
Lenacapavir
▶︎
Immune Reconstitution Syndrome, 2023: Part 1 of 2
▶︎
The Future of HIV Prevention: IGHS Grand Rounds wth Monica Gandhi, MD, MPH
▶︎
CROI 2020 Review: Dual ART & HIV Cure
▶︎
Webinar Long Acting Injectable Antipsychotics in Practice
▶︎
Urinary Tract Infection Pharmacotherapy | TRC Healthcare Medication Talk Podcast
▶︎
PrEP for HIV Prevention: NAT in PrEP
▶︎
CROI 2026 Report Back: Treatment Updates
▶︎
July 7, 2023: Cabenuva/Apretude Procedure Updates - Kilcrease
▶︎
Mini-Lecture Series: Bictegravir-Tenofovir alafenamide-Emtricitabine
▶︎
Safeguarding Transplant Recipients: Measles Risk Reduction Strategies
▶︎
New Therapies for Neisseria gonorrhoeae
▶︎
Long-Acting Injectable Cabotegravir: the Future of HIV PrEP?
▶︎
CROI 2026 Updates: HIV and STI Prevention
▶︎
The Scientific Journey of Lenacapavir: From basic science to clinical development to impact
▶︎
Perinatal HCV Epidemiology and Reporting in West Virginia by Candice Leferber, Kady Pack & Amna Umer
▶︎
Long-acting Cabotegravir/Rilpivirine for Persons who Don’t Fulfill FDA Eligibility Criteria
▶︎